A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo

Overexpression of HER2 has been reported in many types of cancer, making it a perfect candidate for targeted immunotherapy. The combination of two FDA approved monoclonal antibodies (mAbs), trastuzumab and pertuzumab, has more robust anti-tumor activity in patients with HER2-overexpressing breast ca...

Full description

Bibliographic Details
Main Authors: Mehdi Mohammadi, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Mohammad Arjmand, Tannaz Bahadori, Mohammad Ali Judaki, Fariba Shiravi, Hengameh Ahmadi Zare, Farzaneh Notash Haghighat, Maryam Mobini, Mohammad Mehdi Amiri, Fazel Shokri
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
HER2
DVD-Ig
monoclonal antibody
bispecific antibody
cancer immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.600883/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.600883/full

Similar Items